离体肝切除联合自体肝移植治疗肝脏复杂占位性病变的临床疗效

Clinical efficacy of ex vivo liver resection and autotransplantation for liver complex space-occupying lesions

  • 摘要: 目的:探讨离体肝切除联合自体肝移植(ELRA)治疗肝脏复杂占位性病变的临床疗效。
    方法:采用回顾性描述性研究方法。收集2009年6月至2017年5月陆军军医大学第一附属医院收治的50例行ELRA肝脏复杂占位性病变患者的临床病理资料;男36例,女14例;中位年龄为51岁,年龄范围为13~69岁。患者均行ELRA。观察指标:(1)手术情况。(2)术后情况。(3)随访情况。采用门诊或电话方式进行随访。患者出院后前6个月行个体化随访,此后每3~6个月随访1次,了解患者肿瘤复发及生存情况。随访时间截至2019年5月。正态分布的计量资料以±s表示。偏态分布的计量资料以M(范围)表示。计数资料以绝对数或百分比表示。采用Kaplan-Meier法计算生存率并绘制生存曲线。采用Log-rank检验进行生存分析。
    结果:(1)手术情况:50例患者均顺利完成ELRA,术后病理学检查结果示R0切除率为100%(50/50)。50例患者手术时间为(630±186)min,其中9例肝脏良性占位性病变患者手术时间为(684±168)min,41例肝脏恶性肿瘤患者手术时间为(618±190)min。50例患者临时性下腔静脉重建与门腔分流操作时间为(35±9)min,无肝期时间为(256±71)min,术中出血量为2 000 mL(400~10 000 mL),剩余肝脏质量与标准肝脏质量比值为65%±16%,其中9例肝脏良性占位性病变患者剩余肝脏质量与标准肝脏质量比值为63%±14%,41例肝脏恶性肿瘤患者剩余肝脏质量与标准肝脏质量比值为65%±17%。50例患者中,35例血管侵犯(肝脏良性占位性病变7例、肝脏恶性肿瘤28例),其中24例行体外血管整形重建术(肝脏良性占位性病变6例、肝脏恶性肿瘤18例);12例胆管侵犯,因胆总管无法对端吻合行胆肠吻合术(肝脏良性占位性病变5例、肝脏恶性肿瘤7例);2例胃癌肝转移、1例结肠癌肝转移、1例胰腺癌肝转移分别联合行胃癌根治术、结肠癌根治术、胰十二指肠切除术。(2)术后情况:50例患者术后住院时间为25 d(11~169 d)。50例患者中,12例发生胸腔积液,行胸腔穿刺引流术;10例发生胆汁漏,行腹腔穿刺引流术;3例发生胆总管吻合口漏,行经内镜鼻胆管引流或胆道支架植入术;6例行2次手术,其中4例因腹腔出血行剖腹探查术,1例因腹腔出血合并门静脉血栓行剖腹探查门静脉重建术,1例因肝衰竭行抢救性肝移植。 50例患者术后90 d内死亡9例,均为肝脏恶性肿瘤患者,其中3例死于重症感染引起多器官功能障碍综合征,3例死于急性肝衰竭,2例死于腹腔出血,1例死于肺动脉栓塞。(3)随访情况:50例患者均获得随访,随访时间为1~119个月。50例患者ELRA术后总体生存时间为17个月(1~119个月),1、3、5年总体生存率和无瘤生存率分别为68.0%、45.9%、41.1%和41.9%、33.4%、30.8%;9例肝脏良性占位性病变患者 ELRA术后总体生存时间为68个月(10~114个月),1、3、5年总体生存率和无瘤生存率均为88.9%;41例肝脏恶性肿瘤患者ELRA术后总体生存时间为15个月(1~119个月),1、3、5年总体生存率和无瘤生存率分别为63.4%、36.6%、31.0%和31.5%、21.0%、18.0%。肝脏良性占位性病变与肝脏恶性肿瘤患者ELRA术后总体生存率和无瘤生存率比较,差异均有统计学意义(x2=7.626,11.766,P<0.05)。
    结论:ELRA可用于治疗肝脏复杂占位性病变,治疗肝脏恶性肿瘤患者的筛选标准应更加严格,以降低围术期病死率。

     

    Abstract: Objective:To investigate the clinical efficacy of ex vivo liver resection and autotransplantation (ELRA) for liver complex space-occupying lesions.
    Methods:The retrospective and descriptive study was conducted. The clinicopathological data of 50 patients with liver complex space-occupying lesions who underwent ELRA in the First Hospital Affiliated to Army Medical University between June 2009 and May 2017 were collected. There were 36 males and 14 females, aged from 13 to 69 years, with a median age of 51 years. All patients underwent ELRA. Observation indicators: (1) surgical situations; (2) postoperative situations; (3) follow-up. Follow-up was conducted by outpatient examination or telephone interview. Patients were followed up according to the individual follow-up plan in the first 6 months after discharge, and then once every 3 to 6 months to detect tumor recurrence and survival up to May 2019. Measurement data with normal distribution were represented as Mean±SD. Measurement data with skewed distribution were represented as M (range). Count data were expressed as absolute numbers or percentages. The Kaplan-Meier method was used to calculate survival rates and draw survival curves, and Log-rank test was used for survival analysis.
    Results:(1) Surgical situations: all the 50 patients underwent ELRA successfully, and postoperative pathological examination showed the R0 resection rate was 100%(50/50). The operation time of the 50 patients were (630±186)minutes, of which 9 patients with liver benign occupation had the operation time of (684±168)minutes and 41 patients with liver malignant tumor had the operation time of (618±190)minutes. The operation time of temporary reconstruction of inferior vena cava and portacaval shunt, time of anhepatic phase, volume of intraoperative blood loss of the 50 patients were (35± 9)minutes, (256±71)minutes, 2 000 mL(range, 400-10 000 mL), respectively. The remnant liver mass to standard liver mass ratio of the 50 patients was 65%±16%, of which 9 patients with liver benign occupation had the remnant liver mass to standard liver mass ratio of 63%±14% and 41 patients with liver malignant tumor had the remnant liver mass to standard liver mass ratio of 65%±17%. Of the 50 patients, 35 had vascular invasion (7 cases with liver benign occupation, 28 cases with liver malignant tumor), of which 24 (6 cases with liver benign occupation, 18 cases with liver malignant tumor) underwent in vitro vascular reconstruction, 12 (5 cases with liver benign occupation, 7 cases with liver malignant tumor) had bile duct invasion and underwent choledochojejunostomy due to the inability of the common bile duct to anastomose the ends. Two cases with liver metastasis of gastric cancer, one case with liver metastasis of colon cancer and one case with liver metastasis of pancreatic cancer underwent radical gastrectomy, radical resection of colon cancer, and pancreaticoduodenectomy, respectively. (2) Postoperative situations: the duration of postoperative hospital stay of the 50 patients were 25 days (range, 11-169 days). Of the 50 patients, 12 had pleural effusion who were treated with pleural puncture drainage, 10 had bile leakage who were treated with abdominal puncture drainage, 3 had bile duct anastomotic leakage who were treated with endoscopic nasobiliary drainage or biliary stent implantation, 6 underwent reoperation among which 4 underwent exploratory laparotomy due to abdominal hemorrhage, 1 underwent portal vein reconstruction due to abdominal hemorrhage combined with portal vein thrombosis, and 1 underwent salvage liver transplantation due to liver failure. Nine of the 50 patients died within 90 days after surgery, all of whom had liver malignant tumor. Among them, 3 died of multi-organ dysfunction syndrome caused by severe infection, 3 died of acute liver failure, 2 died of abdominal hemorrhage and 1 died pulmonary embolism. (3) Follow-up: all the 50 patients were followed up for 1 to 119 months. The overall survival time, 1-, 3-, 5-year overall and tumor-free survival rates of the 50 patients after operation were 17 months (range, 1-119 months), 68.0%, 45.9%, 41.1% and 41.9%, 33.4%, 30.8%, respectively. The overall survival time, 1-, 3-, 5-year overall and tumor-free survival rates of the 9 patients who with liver benign occupation after operation were 68 months (range, 10- 114 months), 88.9%, 88.9%, 88.9% and 88.9%, 88.9%, 88.9%, respectively. The overall survival time, 1-, 3-, 5-year overall and tumor-free survival rates of the 41 patients who with liver malignant tumor after operation were 15 months (range, 1-119 months), 63.4%, 36.6%, 31.0% and 31.5%, 21.0%, 18.0%, respectively. There were significant differences in the overall and tumor-free survival rates between patients who with liver benign occupation and patients who with liver malignant tumor (x2=7.626, 11.766, P<0.05).
    Conclusions:  ELRA can be applied in the treatment of liver complex space-occupying lesions. The selection criteria of patients with liver malignant tumor should be more rigorous to reduce perioperative mortality.

     

/

返回文章
返回